News & Media

Newsroom

SK Life Science Celebrates Purple Day Highlighting Partnerships and Tools Designed to Empower People Living with Epilepsy in Their Journey to Achieve Zero Seizures

3.25.2024

SK Life Science, Inc., Publishes Updated Real-World Experience on Cenobamate in Epilepsia Based on Recent 100,000 Patient Exposure Milestone

3.13.2024

SK Biopharmaceuticals Announces 100,000 Patients Globally Have Been Treated with Cenobamate Through Sales of XCOPRI® and ONTOZRY® in the U.S., Europe, Israel, and Canada

3.11.2024

SK Life Science to Host Symposium and Present New Data at the American Epilepsy Society (AES) 2023 Annual Meeting

11.20.2023

Latest XCOPRI® (cenobamate tablets) CV Post-hoc Analysis Presented at the 75th American Academy of Neurology Annual Meeting

4.17.2023

Welcome to the news and information center for SK Life Science, Inc.

To learn more about SK Life Science, please download our corporate brochure

For more information about epilepsy, please download this infographic

For more information about Lennox-Gastaut syndrome, please download this fact sheet

X Community Guidelines

LinkedIn Community Guidelines

Bluesky Community Guidelines

SK Life Science at a Glance

Headquarters Location: Paramus, NJ

R&D Begins: 1993

Parent Company: SK Life Science is a subsidiary of SK Biopharmaceuticals, CO., LTD, and both are a part of SK Group

Number of Employees: 200+ Employees

Disease Category Focus: CNS Disorders and Oncology

Pipeline: 8 compounds under clinical development

Top